How are Estrogens adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Estrogens is flagged as the suspect drug causing the adverse event.
What are the most common Estrogens adverse events reported to the FDA?
Breast Cancer | 463 (19.84%) |
Breast Cancer Female | 398 (17.05%) |
Breast Operation | 87 (3.73%) |
Mastectomy | 50 (2.14%) |
Breast Cancer Metastatic | 39 (1.67%) |
Oestrogen Receptor Assay Positive | 25 (1.07%) |
Injury | 24 (1.03%) |
Thrombosis | 23 (.99%) |
Breast Cancer In Situ | 21 (.9%) |
Dyspnoea | 20 (.86%) |
Ovarian Cancer | 20 (.86%) |
Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
What are the most common Estrogens adverse events reported to the FDA?
Breast Neoplasms Malignant And Unsp... | 941 (40.32%) |
Breast Therapeutic Procedures | 150 (6.43%) |
Endocrine Investigations | 53 (2.27%) |
Embolism And Thrombosis | 49 (2.1%) |
Injuries | 46 (1.97%) |
Respiratory | 42 (1.8%) |
Reproductive Neoplasms Female Malig... | 40 (1.71%) |
Neurological | 39 (1.67%) |
Epidermal And Dermal Conditions | 32 (1.37%) |
Therapeutic And Nontherapeutic Effe... | 26 (1.11%) |
Infections - Pathogen Unspecified | 25 (1.07%) |
Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Why are people taking Estrogens, according to those reporting adverse events to the FDA?
Hormone Replacement Therapy | 2132 |
Drug Use For Unknown Indication | 239 |
Menopausal Symptoms | 101 |
Menopause | 88 |
Oestrogen Replacement Therapy | 66 |
Hormone Therapy | 38 |
Show More |
Label | Labeler | Effective |
---|---|---|
Cenestin | Physicians Total Care, Inc. | 01-SEP-04 |
Cenestin | Teva Women's Health Inc. | 01-SEP-04 |
Enjuvia | Physicians Total Care, Inc. | 01-MAR-10 |
Enjuvia | Duramed Pharmaceuticals Inc. | 01-MAR-10 |
Premarin | State of Florida DOH Central Pharmacy | 27-MAY-10 |
Esterified Estrogens And Methyltestosterone | Tal Pharma LLC | 16-SEP-10 |
Premarin | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-NOV-10 |
Esterified Estrogens And Methyltestosterone | Amneal Pharmaceuticals | 07-FEB-11 |
Menest | Monarch Pharmaceuticals, Inc. | 02-SEP-11 |
Premarin | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 21-MAR-12 |
Premarin | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 22-MAR-12 |
Esterified Estrogens And Methyltestosterone | ANIP Acquisition Company | 30-MAR-12 |
Premarin Vaginal | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 10-MAY-12 |
Premarin | Cardinal Health | 22-JUN-12 |
Premarinvaginal | Physicians Total Care, Inc. | 22-JUN-12 |
Premarin | Aphena Pharma Solutions - Tennessee, Inc. | 18-JUL-12 |
Premarin | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-JUL-12 |
Premphase | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-SEP-12 |
Prempro | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-SEP-12 |
Prempro | Physicians Total Care, Inc. | 01-NOV-12 |
Premphase | Physicians Total Care, Inc. | 26-NOV-12 |
Prempro | Dispensing Solutions, Inc. | 27-FEB-13 |
Eemt | CREEKWOOD PHARMACEUTICAL, INC, | 01-MAR-13 |
Eemt Hs | CREEKWOOD PHARMACEUTICAL, INC, | 01-MAR-13 |
Premarin | Cardinal Health | 17-APR-13 |
Esterified Estrogens And Methyltestosterone | ANIP Acquisition Company | 29-APR-13 |
Esterified Estrogens And Methyltestosterone | Amneal Pharmaceuticals, LLC | 30-APR-13 |
Premarin | Cardinal Health | 30-APR-13 |
What Estrogens safety concerns are being reported by doctors and researchers in the medical literature?
This report contains aggregated drug side effects and adverse events for Estrogens. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Share your experience with Estrogens.